Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP3A5 polymorphism and ImmuKnow-guided CNI dosing in Chinese liver transplant recipients
ChiCTR-IIR-16008040Phase 3Completed
- Sponsor
- Renji Hospital
- Start
- Oct 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in acute liver rejection (ACR) (2 arms), sponsored by Renji Hospital. Primary endpoint: Incidence of acute rejection. Started Oct 2011; status: completed.
02
Drugs
tacrolimus
03
Conditions
acute liver rejection (ACR)
Beyond the preview
Go deeper on ChiCTR-IIR-16008040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008040.